Schrodinger (SDGR)

• Market cap: $1.58B
• 1 day: 8.52%
• 5 days: 2.17%
• 1 month: -11.56%
• 3 months: -0.46%
• 6 months: 5.25%
• Year to date: 6.18%
• 1 year: -18.39%
• 5 years: -39.02%
• 10 years: -24.37%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Employees: 787

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

48% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $6.93M

26% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 27

7% more capital invested

Capital invested by funds: $1.12B [Q3] → $1.19B (+$75.2M) [Q4]

2.49% more ownership

Funds ownership: 94.7% [Q3] → 97.19% (+2.49%) [Q4]

2% more funds holding

Funds holding: 205 [Q3] → 210 (+5) [Q4]

17% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 76

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 25% upside
• Avg. target: $36 66% upside
• High target: $45 108% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Joseph Catanzaro 40% 1-year accuracy 12 / 30 met price target	108% upside $45	Overweight Maintained	27 Feb 2025
Keybanc Scott Schoenhaus 29% 1-year accuracy 9 / 31 met price target	25% upside $27	Overweight Maintained	24 Jan 2025